Completed PHASE1 INTERVENTIONAL 4-arm NCT01810315

Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity

Influence of Female Reproductive Cycle and Menopause on Cervicovaginal Tissue Susceptibility to HIV-1 Infections and Tenofovir 1% Gel Activity

Sponsor: CONRAD

Conditions HIV Prevention

Interventions Estradiol vaginal cream TFV 1% gel

Updated 6 times since 2017 Last updated: Apr 9, 2015 Started: Sep 30, 2013 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HIV Prevention, this trial is completed. The trial is conducted by CONRAD and has accumulated 6 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CONRAD

Data source: CONRAD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Norfolk, United States